
|Articles|March 1, 2002
Unoprostone lowers IOP in advanced glaucoma cases
Washington, DC-Unoprostone isopropyl 0.15% (Rescula, Novartis) may be a viable option for further lowering IOP in patients with advanced glaucoma whose disease is uncontrolled by maximum tolerated medical therapy, said Leslie S. Jones, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5






















